Related Experiment Video
Updated: Nov 15, 2025

07:18
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
7.2K
Histiocytic Sarcoma: Challenging Course, Dismal Outcome
Kim Francis Andersen1, Lene Dissing Sjö2, Peter Kampmann3
1Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Diagnostics (Basel, Switzerland)
|March 6, 2021
Summary
Histiocytic sarcoma (HS) is a rare cancer. This case highlights the diagnostic challenges and aggressive nature of HS, emphasizing the need for effective treatment strategies.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Histiocytic sarcoma (HS) is a rare hematopoietic neoplasm originating from the monocyte/macrophage system.
- It affects individuals across a wide age range with a slight male predominance.
- HS can present as a localized mass or disseminated disease with extranodal involvement.
Purpose of the Study:
- To report a case of histiocytic sarcoma in a previously healthy male.
- To illustrate the diagnostic difficulties associated with this rare malignancy.
- To highlight the aggressive clinical course and treatment challenges of HS.
Main Methods:
- Case report of a 43-year-old male presenting with abdominal pain and fatigue.
- Review of diagnostic work-up challenges for histiocytic sarcoma.
- Discussion of treatment strategies and clinical outcomes for HS.
Main Results:
- The patient presented with symptoms suggestive of a serious underlying condition.
- Diagnostic work-up revealed histiocytic sarcoma, underscoring diagnostic complexities.
- The disease demonstrated an aggressive clinical course, consistent with known HS behavior.
Conclusions:
- Histiocytic sarcoma poses significant diagnostic and therapeutic challenges due to its rarity and aggressive nature.
- Early and accurate diagnosis is crucial for managing HS, despite limited standardized treatment options.
- This case emphasizes the poor prognosis associated with disseminated histiocytic sarcoma.

